Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases

被引:162
|
作者
Zordoky, Beshay N. M. [1 ]
El-Kadi, Ayman O. S. [1 ]
机构
[1] Univ Alberta, Fac Pharm & Pharmaceut Sci, Dent Pharm Ctr 3126, Edmonton, AB T6G 2N8, Canada
关键词
Cardiovascular disease; Cytochrome P450; Arachidonic acid; Soluble epoxide hydrolase; Genetic polymorphism; SOLUBLE EPOXIDE HYDROLASE; CORONARY-ARTERY-DISEASE; SMOOTH-MUSCLE-CELLS; ACTIVATED PROTEIN-KINASE; CEREBRAL-BLOOD-FLOW; MEPHENYTOIN HYDROXYLATION PHENOTYPE; HUMAN LIVER-MICROSOMES; HUMAN CYP4A11 GENE; LUNG-CANCER RISK; EPOXYEICOSATRIENOIC ACIDS;
D O I
10.1016/j.pharmthera.2009.12.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cardiovascular diseases (CVDs) remain the leading cause of death in the developed countries. Taking into account the mounting evidence about the role of cytochrome P450 (CYP) enzymes in cardiovascular physiology, CYP polymorphisms can be considered one of the major determinants of individual susceptibility to CVDs. One of the important physiological roles of CYP enzymes is the metabolism of arachidonic acid. CYP epoxygenases such as CYP1A2, CYP2C, and CYP2J2 metabolize arachidonic acid to epoxyeicosatrienoic acids (EETs) which generally possess vasodilating, anti-inflammtory, anti-apoptotic, anti-thrombotic, natriuretic. and cardioprotective effects. Therefore, genetic polymorphisms causing lower activity of these enzymes are generally associated with an increased risk of several CVDs such as hypertension and coronary artery disease. EETs are further metabolized by soluble epoxide hydrolase (sEH) to the less biologically active dihydroxyeicosatrienoic acids (DHETs). Therefore, sEH polymorphism has also been shown to affect arachidonic acid metabolism and to be associated with CVDs. On the other hand. CYP to-hydroxylases such as CYP4A11 and CYP4F2 metabolize arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE) which has both vasoconstricting and natriuretic effects. Genetic polymorphisms causing lower activity of these enzymes are generally associated with higher risk of hypertension. Nevertheless, some studies have denied the association between polymorphisms in the arachidonic acid pathway and CVDs. Therefore, more research is needed to confirm this association and to better understand the pathophysiologic mechanisms behind it. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:446 / 463
页数:18
相关论文
共 50 条
  • [31] Effect of alcohol on cytochrome P450 arachidonic acid metabolism and blood pressure in rats and its modulation by red wine polyphenolics
    Cowpland, C
    Su, GM
    Murray, M
    Puddey, IB
    Croft, KD
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2006, 33 (03): : 183 - 188
  • [32] Cytochrome P450 and liver diseases
    Villeneuve, JP
    Pichette, V
    CURRENT DRUG METABOLISM, 2004, 5 (03) : 273 - 282
  • [33] Cytochrome P450 and radiopharmaceutical metabolism
    Giron, M. C.
    Portolan, S.
    Bin, A.
    Mazzi, U.
    Cutler, C. S.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 52 (03): : 254 - 266
  • [34] Cytochrome P450 metabolism of bupropion
    Goodale, E
    Ascher, J
    Batey, S
    BIOLOGICAL PSYCHIATRY, 1999, 45 (08) : 75S - 75S
  • [35] Porcine cytochrome P450 and metabolism
    Skaanild, Mette Tingleff
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (11) : 1421 - 1427
  • [36] Cytochrome P450 metabolism of bupropion
    Ascher, J
    Batey, S
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1999, 47 (09) : S88 - S88
  • [37] Metabolism prediction for cytochrome P450
    Zamora, I
    Ridderström, M
    Vianello, R
    Cruciani, G
    Anderson, TB
    DRUG METABOLISM REVIEWS, 2003, 35 : 39 - 39
  • [38] Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease
    Minuz, Pietro
    Jiang, Houli
    Fava, Cristiano
    Turolo, Lucia
    Tacconelli, Stefania
    Ricci, Marco
    Patrignani, Paola
    Morganti, Alberto
    Lechi, Alessandro
    McGiff, John C.
    HYPERTENSION, 2008, 51 (05) : 1379 - 1385
  • [39] CYTOCHROME P450 EPOXYGENASE PRODUCTS OF ARACHIDONIC ACID ARE ALTERED IN THE METABOLIC SYNDROME
    Barden, A.
    Tsai, I. J.
    Indrawan, A.
    Puddey, I. B.
    Beilin, L. J.
    Croft, K. D.
    HYPERTENSION, 2010, 55 (06) : 1495 - 1495
  • [40] Cytochrome P450 arachidonic acid metabolites modulate renal tubular function
    Carroll, MA
    Ferreri, NR
    Escalante, BA
    Oyekan, AO
    McGiff, JC
    ADVANCES IN PROSTAGLANDIN, LEUKOTRIENE, AND OTHER BIOACTIVE LIPID RESEARCH: BASIC SCIENCE AND CLINICAL APPLICATIONS, 2003, 525 : 67 - 69